Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6M0T

Crystal Structure of Lysyl-tRNA Synthetase from Plasmodium falciparum complexed with L-lysine and Cladosporin derivative (CL-2)

Summary for 6M0T
Entry DOI10.2210/pdb6m0t/pdb
Related4PG3
DescriptorLysine--tRNA ligase, LYSINE, (3R)-3-[(R)-[(2R,6S)-6-methyloxan-2-yl]-oxidanyl-methyl]-6,8-bis(oxidanyl)-3,4-dihydroisochromen-1-one, ... (4 entities in total)
Functional Keywordscladosporin analog, stereochemistry, ligase-ligase inhibitor complex, ligase/ligase inhibitor
Biological sourcePlasmodium falciparum 3D7
Total number of polymer chains4
Total formula weight236649.82
Authors
Babbar, P.,Sharma, A.,Manickam, Y. (deposition date: 2020-02-22, release date: 2021-04-21, Last modification date: 2024-10-23)
Primary citationBabbar, P.,Das, P.,Manickam, Y.,Mankad, Y.,Yadav, S.,Parvez, S.,Sharma, A.,Reddy, D.S.
Design, Synthesis, and Structural Analysis of Cladosporin-Based Inhibitors of Malaria Parasites.
Acs Infect Dis., 7:1777-1794, 2021
Cited by
PubMed Abstract: Here we have described a systematic structure activity relationship (SAR) of a set of compounds inspired from cladosporin, a tool compound that targets parasite () lysyl tRNA synthetase (KRS). Four sets of analogues, synthesized based on point changes in the chemical scaffold of cladosporin and other logical modifications and hybridizations, were assessed using high throughput enzymatic and parasitic assays along with pharmacokinetics. Co-crystallization of the most potent compound in our series () with KRS revealed its structural basis of enzymatic binding and potency. Further, we report that has performed better than cladosporin in terms of metabolic stability. It thus represents a new lead for further optimization toward the development of antimalarial drugs. Collectively, along with a lead compound, the series offers insights on how even the slightest chemical modification might play an important role in enhancing or decreasing the potency of a chemical scaffold.
PubMed: 33843204
DOI: 10.1021/acsinfecdis.1c00092
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.68 Å)
Structure validation

249697

PDB entries from 2026-02-25

PDB statisticsPDBj update infoContact PDBjnumon